Preview: U.S. panel seen backing Pfizer’s arthritis drug hope

WASHINGTON (Reuters) – Pfizer Inc’s experimental rheumatoid arthritis drug goes before an advisory panel next week, a potential blockbuster medicine that would revive faith in the company’s research if its benefits are deemed to outweigh its side effects.